Showing 1 - 10 of 37
Our review confirmed that the BIA is not yet a well-established technique in the literature and many published studies still fail to reach an acceptable quality. In particular, BIAs funded by pharmaceutical companies appear to be tailored to show short-term savings induced by new, highly priced...
Persistent link: https://www.econbiz.de/10011000857
The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by...
Persistent link: https://www.econbiz.de/10011001463
Persistent link: https://www.econbiz.de/10010539841
Persistent link: https://www.econbiz.de/10011151220
Persistent link: https://www.econbiz.de/10011241533
Persistent link: https://www.econbiz.de/10010634521
Psoriasis is a chronic, immune-mediated skin disorder that affects 1–3% of the general population worldwide. While considered a non-life-threatening disease, psoriasis represents a social and financial burden for patients and the healthcare system. Individuals suffer from disfigurement and...
Persistent link: https://www.econbiz.de/10010848964
Persistent link: https://www.econbiz.de/10011000736
Objective: To offer cost estimates of urinary incontinence (UI) in the general population based on prospectively collected data. Design: We analysed individual costs in a sample of women with UI who were identified in the framework of a cross-sectional study on the prevalence of UI in women aged...
Persistent link: https://www.econbiz.de/10005243106
It is remarkable how health care systems, created over decades and influenced by very different cultures exhibit similar problems. Most health care systems are compartmentalised with managers at margins responding to perverse incentives and seeking to shift patients and costs onto rival...
Persistent link: https://www.econbiz.de/10005344362